Skip to main content
. 2019 Oct 29;8(5):367–373. doi: 10.1093/gastro/goz056

Table 2.

Relationships between patients’ characteristics and responses

Demographics and clinical characteristic Primary non-responders (n = 17) Primary responders (n = 119) P-valuea
Sex 0.377
 Male, n (%) 11 (64.7) 90 (75.6)
 Female, n (%) 6 (35.3) 29 (24.4)
Age, years, median [IQR] 23.0 [15.5–32.0] 23.0 [18.0–28.0] 0.916
BMI, kg/m2, median [IQR] 18.6 [16.5–20.4] 18.0 [16.4–19.5] 0.525
Disease duration, years, median [IQR] 2.0 [0.8–3.0] 1.0 [0.5–3.0] 0.468
Disease behavior, n (%) 0.431
 B1 13 (76.5) 98 (82.4)
 B2 1 (5.9) 8 (6.7)
 B3 3 (17.6) 10 (8.4)
 B2 + B3 0 (0) 3 (2.5)
Disease location, n (%) 0.621
 L1 0 (0) 10 (8.4)
 L2 1 (5.9) 3 (2.5)
 L3 15 (88.2) 92 (77.3)
 L1 + L4 0 (0) 2 (1.7)
 L2 + L4 0 (0) 0 (0)
 L3 + L4 1 (5.9) 12 (10.1)
Perianal lesions, n (%) 14 (82.4) 91 (76.5) 0.762
Previous bowel surgery, n (%) 1 (5.9) 16 (13.4) 0.695
Combined with thiopurine, n (%) 9 (52.9) 69 (59.0) 0.694
Albumin at baseline, g/L, mean ± SD 36.1 [31.7–39.7] 38.4 [34.5–42.1] 0.111
Hemoglobin at baseline, mg/dL, mean ± SD 115.0 [93.0–127.5] 114.0 [95.0–126.4] 0.851
hs-CRP at baseline, mg/L, median [IQR] 12.1 [9.2–33.0] 11.8 [9.5–18.8] 0.512
ESR at baseline, mm/h, median [IQR] 55.0 [41.0–68.5] 38.5 [27.0–64.0] 0.038
CRP at baseline, mg/L, median [IQR] 22.6 [7.4–50.2] 20.0 [10.6–38.7] 0.911
CRP at 14th week, mg/L, median [IQR] 9.4 [2.9–28.4] 1.0 [0.5–3.8] <0.001
IFX level at 14th week, μg/mL, median [IQR] 1.7 [0.6–4.0] 3.3 [1.3–6.0] 0.042

BMI, body mass index; B1, non-stricturing non-penetrating; B2, structuring; B3, penetrating; L1, terminal ileum; L2, colon; L3, ileocolon; L4, upper gastrointestinal; hs-CRP, high sensitive C reaction protein; IFX, infliximab.

a

Chi-square tests or Mann–Whitney U test; those P-values <0.05 are highlighted in bold font.